Lantheus executives discussed stabilizing PYLARIFY sales through strategic partnerships, divesting the SPECT business for future growth, and focusing on PET radiodiagnostics. The company anticipates double-digit revenue growth in 2026 driven by new product launches and acquisitions.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing